Literature DB >> 15703905

Sickle cell diseases: current therapeutic options and potential pitfalls in preventive therapy for transcranial Doppler abnormalities.

Sharada A Sarnaik1.   

Abstract

Sickle cell disease is an important and common hemoglobinopathy that is highly prevalent worldwide. Recent clinical research has clarified the natural history, and newer, exciting therapeutic maneuvers have been developed, including stem cell transplantation, a curative, albeit toxic strategy. There is a need for early identification of a severe disease profile so that these newer therapeutic interventions can be offered before severe organ damage occurs. Investigative methodologic research by radiologists to discover early organ damage can be important to successful planning of treatment protocols. Stroke is one complication, which, if diagnosed early, can be satisfactorily managed with more aggressive therapy. The advent of transcranial Doppler and MRI have greatly increased the ability to detect early CNS disease.

Entities:  

Mesh:

Year:  2005        PMID: 15703905     DOI: 10.1007/s00247-005-1408-8

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  32 in total

1.  Bone marrow transplantation without myeloablation for sickle cell disease.

Authors:  L Krishnamurti; B R Blazar; J E Wagner
Journal:  N Engl J Med       Date:  2001-01-04       Impact factor: 91.245

2.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

Review 3.  Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion.

Authors:  R B Francis
Journal:  Blood Coagul Fibrinolysis       Date:  1991-04       Impact factor: 1.276

Review 4.  The role of rib infarcts in the acute chest syndrome of sickle cell diseases.

Authors:  D L Rucknagel
Journal:  Pediatr Pathol Mol Med       Date:  2001 Mar-Apr

5.  The natural history of stroke in sickle cell disease.

Authors:  D Powars; B Wilson; C Imbus; C Pegelow; J Allen
Journal:  Am J Med       Date:  1978-09       Impact factor: 4.965

6.  Molecular characteristics of pediatric patients with sickle cell anemia and stroke.

Authors:  S A Sarnaik; S K Ballas
Journal:  Am J Hematol       Date:  2001-07       Impact factor: 10.047

7.  Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Authors:  S Charache; F B Barton; R D Moore; M L Terrin; M H Steinberg; G J Dover; S K Ballas; R P McMahon; O Castro; E P Orringer
Journal:  Medicine (Baltimore)       Date:  1996-11       Impact factor: 1.889

8.  Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler.

Authors:  R J Adams; V C McKie; E M Carl; F T Nichols; R Perry; K Brock; K McKie; R Figueroa; M Litaker; S Weiner; D Brambilla
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

9.  Thrombospondin mediates adherence of CD36+ sickle reticulocytes to endothelial cells.

Authors:  K Sugihara; T Sugihara; N Mohandas; R P Hebbel
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

10.  Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study.

Authors:  Robert J Adams; Donald J Brambilla; Suzanne Granger; Dianne Gallagher; Elliott Vichinsky; Miguel R Abboud; Charles H Pegelow; Gerald Woods; Elizabeth M Rohde; Fenwick T Nichols; Anne Jones; Judith P Luden; Latonya Bowman; Susan Hagner; Knashawn H Morales; E Steve Roach
Journal:  Blood       Date:  2004-01-29       Impact factor: 22.113

View more
  2 in total

1.  Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results.

Authors:  Margaret T Lee; Sergio Piomelli; Suzanne Granger; Scott T Miller; Shannon Harkness; Donald J Brambilla; Robert J Adams
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

2.  Randomized trial of hypnosis as a pain and symptom management strategy in adults with sickle cell disease.

Authors:  Gwenyth R Wallen; Kimberly R Middleton; Nancy Ames; Alyssa T Brooks; Daniel Handel
Journal:  Integr Med Insights       Date:  2014-11-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.